Evidence map›Paper›PMID 25906443›Full record

ArticlePancreas2015

In vivo risk analysis of pancreatic cancer through optical characterization of duodenal mucosa.

Nikhil N Mutyal, Andrew J Radosevich, Shailesh Bajaj, Vani Konda, Uzma D Siddiqui, Irving Waxman, Michael J Goldberg, Jeremy D Rogers, Bradley Gould, Adam Eshein and 5 more

Open access · hybridAbstract readEvaluation Study
In one paragraph

Article in Pancreas, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.7field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 16 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Review
  5. Microscope objective based 4Biomedical optics express · 2017
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 3 institutions in 1 country.

Nikhil N MutyalFrom the *Department of Biomedical Engineering, Northwestern University; †Department of Internal Medicine, NorthShore University HealthSystems, Evanston; ‡Center for Endoscopic Research and Therapeutics, University of Chicago Medicine, Chicago, IL; and §Department of Gastroenterology, Boston Medical Center, Boston, MA.
Andrew J Radosevich
Shailesh Bajaj
Vani Konda
Uzma D Siddiqui
Irving Waxman
Michael J Goldberg
Jeremy D Rogers
Bradley Gould
Adam Eshein
Sudeep Upadhye
Ann Koons
Mariano Gonzalez-Haba Ruiz
Hemant K Roy
Vadim Backman
University of Chicago · USNorthShore University HealthSystem · USBoston Medical Center · US

Funding

Tumor Environment and Metastasis (TEAM) Research ProgramP30CA060553 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI Daniela E Matei · 1993 to 2026
$153.9M
Novel Biophotonics Methodology for Colon Cancer ScreeningR01CA128641 · NCI · NORTHWESTERN UNIVERSITY · PI BACKMAN, VADIM · 2008 to 2012
$7.3M
Spectral Markers for Early Detection of Colon NeoplasiaU01CA111257 · NCI · NORTHSHORE UNIV HEALTHSYSTEM RES INST · PI BACKMAN, VADIM, ROY, HEMANT K. · 2004 to 2015
$6.0M
Transforming Colorectal Cancer Screening through Multimodal Spectral MarkersR01CA156186 · NCI · ENDEAVOR HEALTH CLINICAL OPERATIONS · PI BACKMAN, VADIM, ROY, HEMANT K. · 2011 to 2015
$2.8M
Mechanisms of Light Scattering in Living TissuesR01EB003682 · NIBIB · NORTHWESTERN UNIVERSITY · PI BACKMAN, VADIM, PRADHAN, PRABHAKAR · 2005 to 2013
$2.2M
NCI NIH HHS P30 CA060553NCI NIH HHS R01 CA128641NCI NIH HHS R01CA128641NCI NIH HHS R01 CA156186NCI NIH HHS R01CA156186NCI NIH HHS U01 CA111257NCI NIH HHS U01CA111257NIBIB NIH HHS R01 EB003682NIBIB NIH HHS R01EB003682
6 · The paper itself

Abstract

objectivesTo reduce pancreatic cancer mortality, a paradigm shift in cancer screening is needed. Our group pioneered the use of low-coherence enhanced backscattering (LEBS) spectroscopy to predict the presence of pancreatic cancer by interrogating the duodenal mucosa. A previous ex vivo study (n = 203) demonstrated excellent diagnostic potential: sensitivity, 95%; specificity, 71%; and accuracy, 85%. The objective of the current case-control study was to evaluate this approach in vivo.

methodsWe developed a novel endoscope-compatible fiber-optic probe to measure LEBS in the periampullary duodenum of 41 patients undergoing upper endoscopy. This approach enables minimally invasive detection of the ultrastructural consequences of pancreatic field carcinogenesis.

resultsThe LEBS parameters and optical properties were significantly altered in patients harboring adenocarcinomas (including early-stage) throughout the pancreas relative to healthy controls. Test performance characteristics were excellent with sensitivity = 78%, specificity = 85%, and accuracy = 81%. Moreover, the LEBS prediction rule was not confounded by patients' demographics.

conclusionWe demonstrate the feasibility of in vivo measurement of histologically normal duodenal mucosa to predict the presence of adenocarcinoma throughout the pancreas. This represents the next step in establishing duodenal LEBS analysis as a prescreening technique that identifies clinically asymptomatic patients who are at elevated risk of PC.

Indexed as

AdenocarcinomaAdultAgedCase-Control StudiesDuodenoscopesDuodenoscopyDuodenumEquipment DesignFeasibility StudiesFemaleFiber Optic TechnologyHumansIntestinal MucosaMaleMiddle AgedNeoplasm Staging

Identifiers

PMID25906443
PMCPMC4464933
OpenAlexW2316168910

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.